Skip to main content
. 2024 Jul 17;9:175. doi: 10.1038/s41392-024-01856-7

Table 1.

Summary of tumor-related peptide drugs ranked in the global top 25 sales of peptide drugs in 2022

Product Name Company Disease Approval Date 2022 sales revenue (in billions USD)
Sandostatin Novartis Tumour 1988 12.38
Zoladex AstraZenca Cancer 1989 9.27
Decapeptyl Ipsen Hormone-dependent prostate cancer 1986 5.57
Lutathera Novartis Gastrointestinal pancreatic neuroendocrine tumor 2017 4.71